Morgan Stanley’s Theravance Biopharma TBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12M | Buy |
705,202
+194,930
| +38% | +$3.23M | ﹤0.01% | 3550 |
|
|
2026
Q1 | $8.28M | Sell |
510,272
-292,847
| -36% | -$5.18M | ﹤0.01% | 3729 |
|
|
2025
Q4 | $15M | Buy |
803,119
+203,568
| +34% | +$3.38M | ﹤0.01% | 3200 |
|
|
2025
Q3 | $8.75M | Buy |
599,551
+48,944
| +9% | +$618K | ﹤0.01% | 3661 |
|
|
2025
Q2 | $6.07M | Buy |
550,607
+165,620
| +43% | +$1.61M | ﹤0.01% | 3894 |
|
|
2025
Q1 | $3.44M | Sell |
384,987
-7,346
| -2% | -$68.4K | ﹤0.01% | 4226 |
|
|
2024
Q4 | $3.69M | Sell |
392,333
-103,480
| -21% | -$942K | ﹤0.01% | 4250 |
|
|
2024
Q3 | $4M | Buy |
495,813
+36,890
| +8% | +$320K | ﹤0.01% | 4129 |
|
|
2024
Q2 | $3.89M | Buy |
458,923
+39,810
| +9% | +$359K | ﹤0.01% | 4091 |
|
|
2024
Q1 | $3.76M | Buy |
419,113
+155,664
| +59% | +$1.44M | ﹤0.01% | 4143 |
|
|
2023
Q4 | $2.96M | Buy |
263,449
+10,828
| +4% | +$109K | ﹤0.01% | 4278 |
|
|
2023
Q3 | $2.18M | Buy |
252,621
+29,394
| +13% | +$284K | ﹤0.01% | 4343 |
|
|
2023
Q2 | $2.31M | Sell |
223,227
-129,676
| -37% | -$1.43M | ﹤0.01% | 4330 |
|
|
2023
Q1 | $3.83M | Sell |
352,903
-134,920
| -28% | -$1.43M | ﹤0.01% | 3993 |
|
|
2022
Q4 | $5.47M | Sell |
487,823
-110,842
| -19% | -$1.16M | ﹤0.01% | 3676 |
|
|
2022
Q3 | $6.07M | Buy |
598,665
+205,080
| +52% | +$1.92M | ﹤0.01% | 3508 |
|
|
2022
Q2 | $3.56M | Sell |
393,585
-276,419
| -41% | -$2.55M | ﹤0.01% | 4063 |
|
|
2022
Q1 | $6.41M | Sell |
670,004
-809,025
| -55% | -$7.93M | ﹤0.01% | 3412 |
|
|
2021
Q4 | $16.3M | Buy |
1,479,029
+950,477
| +180% | +$8.28M | ﹤0.01% | 2380 |
|
|
2021
Q3 | $3.91M | Buy |
528,552
+80,582
| +18% | +$901K | ﹤0.01% | 3980 |
|
|
2021
Q2 | $6.5M | Buy |
447,970
+289,099
| +182% | +$5.43M | ﹤0.01% | 3497 |
|
|
2021
Q1 | $3.24M | Sell |
158,871
-431,110
| -73% | -$8.19M | ﹤0.01% | 3852 |
|
|
2020
Q4 | $10.5M | Buy |
589,981
+467,538
| +382% | +$8.39M | ﹤0.01% | 2463 |
|
|
2020
Q3 | $1.81M | Sell |
122,443
-280,092
| -70% | -$5.25M | ﹤0.01% | 3744 |
|
|
2020
Q2 | $8.45M | Sell |
402,535
-145,135
| -27% | -$3.73M | ﹤0.01% | 2121 |
|
|
2020
Q1 | $12.7M | Sell |
547,670
-57,186
| -9% | -$1.43M | ﹤0.01% | 1598 |
|
|
2019
Q4 | $15.7M | Buy |
604,856
+100,848
| +20% | +$1.96M | ﹤0.01% | 1893 |
|
|
2019
Q3 | $9.82M | Sell |
504,008
-55,082
| -10% | -$1.11M | ﹤0.01% | 2151 |
|
|
2019
Q2 | $9.13M | Sell |
559,090
-128,302
| -19% | -$2.6M | ﹤0.01% | 2265 |
|
|
2019
Q1 | $15.6M | Buy |
687,392
+61,241
| +10% | +$1.55M | ﹤0.01% | 1635 |
|
|
2018
Q4 | $16M | Buy |
626,151
+508,426
| +432% | +$13.7M | ﹤0.01% | 1661 |
|
|
2018
Q3 | $3.85M | Buy |
117,725
+15,919
| +16% | +$434K | ﹤0.01% | 3458 |
|
|
2018
Q2 | $2.31M | Buy |
101,806
+154
| +0.2% | +$3.66K | ﹤0.01% | 3933 |
|
|
2018
Q1 | $2.46M | Buy |
101,652
+5,415
| +6% | +$149K | ﹤0.01% | 3793 |
|
|
2017
Q4 | $2.68M | Buy |
96,237
+33,051
| +52% | +$978K | ﹤0.01% | 3758 |
|
|
2017
Q3 | $2.16M | Sell |
63,186
-10,620
| -14% | -$347K | ﹤0.01% | 3810 |
|
|
2017
Q2 | $2.94M | Buy |
73,806
+6,688
| +10% | +$257K | ﹤0.01% | 3424 |
|
|
2017
Q1 | $2.47M | Sell |
67,118
-55,404
| -45% | -$1.77M | ﹤0.01% | 3617 |
|
|
2016
Q4 | $3.91M | Buy |
122,522
+95,272
| +350% | +$2.96M | ﹤0.01% | 3257 |
|
|
2016
Q3 | $987K | Sell |
27,250
-5,547
| -17% | -$154K | ﹤0.01% | 4052 |
|
|
2016
Q2 | $745K | Buy |
32,797
+24,983
| +320% | +$539K | ﹤0.01% | 4189 |
|
|
2016
Q1 | $147K | Buy |
7,814
+1,831
| +31% | +$30K | ﹤0.01% | 5145 |
|
|
2015
Q4 | $98K | Buy |
5,983
+444
| +8% | +$7.05K | ﹤0.01% | 5417 |
|
|
2015
Q3 | $61K | Sell |
5,539
-16,055
| -74% | -$204K | ﹤0.01% | 5652 |
|
|
2015
Q2 | $281K | Buy |
21,594
+9,643
| +81% | +$150K | ﹤0.01% | 5072 |
|
|
2015
Q1 | $207K | Sell |
11,951
-163,752
| -93% | -$3M | ﹤0.01% | 5188 |
|
|
2014
Q4 | $2.62M | Buy |
175,703
+80,845
| +85% | +$1.41M | ﹤0.01% | 3316 |
|
|
2014
Q3 | $2.19M | Buy |
94,858
+88,134
| +1,311% | +$2.56M | ﹤0.01% | 3356 |
|
|
2014
Q2 | $214K | Buy |
+6,724
| New | +$202K | ﹤0.01% | 5115 |
|
Other funds holding TBPH
MAP
WAM
NM
ICM
Morgan Stanley's TBPH Position: Q2 2026 in Review
Morgan Stanley increased its Theravance Biopharma (TBPH) stake by 38% in Q2 2026, buying an estimated $3.23M and bringing the position to 705,202 shares worth $12M. The position accounts for ﹤0.01% of the portfolio, ranked #3550.
Morgan Stanley first reported a position in TBPH in Q2 2014 and has held it in 49 quarters since. The position peaked at $16.3M in Q4 2021. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.
- Morgan Stanley held 705,202 shares of Theravance Biopharma worth $12M as of Q2 2026.
- Morgan Stanley bought 194,930 Theravance Biopharma shares in Q2 2026, an estimated $3.23M.
- Theravance Biopharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3550 holding.
- Morgan Stanley first reported a position in Theravance Biopharma in Q2 2014 and has held it in 49 quarters since.
- Morgan Stanley's Theravance Biopharma position peaked at $16.3M in Q4 2021.
- 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.